荷兰对弥漫性脑桥内生型胶质瘤患儿的诊断与治疗的二十年回顾。
A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands.
作者信息
Veldhuijzen van Zanten Sophie E M, Jansen Marc H A, Sanchez Aliaga Esther, van Vuurden Dannis G, Vandertop W Peter, Kaspers Gertjan J L
机构信息
Department of Pediatrics, Division of Oncology/Hematology, VU University Medical Center, De Boelelaan 1118, Room KTC4.027, 1081 HZ Amsterdam, The Netherlands.
出版信息
Expert Rev Anticancer Ther. 2015 Feb;15(2):157-64. doi: 10.1586/14737140.2015.974563. Epub 2014 Nov 29.
INTRODUCTION
Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.
METHODS
We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.
RESULTS
The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.
DISCUSSION
Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.
引言
弥漫性脑桥内在型胶质瘤（DIPG）患儿预后不佳，中位总生存期为9个月。我们的目标是确定荷兰DIPG的发病率，并找出临床研究中有待改进之处，这是增加治愈机会的先决条件。
方法
我们通过评估1990年至2010年间荷兰所有诊断为DIPG的儿童进行了一项基于人群的回顾性队列研究。
结果
荷兰DIPG的发病率与国际文献一致。1990年至2010年间，治疗方案存在很大差异，只有少数患者被纳入临床试验。
讨论
鉴于DIPG的罕见性，我们强调需要开展（跨）国际试验，以便未来能够确定潜在有效的治疗方法。欧洲DIPG登记处的最新发展有助于开展国际研究合作，可为这一目标提供支持。
Zotero 插件